Healthcare Jan 10, 2022 09:00 PM (GMT+8) · EqualOcean
Billion Europe health learned on the 10th that Bristol Myers Squibb (BMS) and century jointly announced a research cooperation and licensing agreement to develop and commercialize up to four therapeutic projects derived from induced pluripotent stem cells (IPSC), engineered natural killer cells (ink) and / or T cells (it) for hematological malignancies and solid tumors. According to the terms of cooperation, century will be responsible for developing candidate discovery and preclinical development activities, and Bristol Myers Squibb will be responsible for subsequent clinical development and commercialization activities. In addition, Bristol Myers Squibb can choose to add two additional items according to certain conditions agreed with century. It is reported that in this cooperation, century will receive US $150 million in cash (US $100 million in advance and US $50 million in equity investment), and may receive more than US $3 billion in development, regulatory and commercial milestone payments.

This text is a result of machine translation.